Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Eisen Kapitel lesen Erstes Kapitel lesen

2016 | OriginalPaper | Buchkapitel

2. Erythropoese stimulierende Pharmaka (ESP)

verfasst von : Prof. Dr. med. Thomas Frietsch

Erschienen in: Transfusionsassoziierte Pharmakotherapie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die perioperative Therapie mit Erythropoese stimulierenden Pharmaka (ESP) zur Vermeidung von allogenen Bluttransfusionen vermeidet Komplikationen, verkürzt die Verweildauer, verringert die Wiederaufnahmerate und ist kostendeckend, wenn sie differenziert als individuelles Hämotherapiekonzept für den jeweiligen Patienten etabliert und eingesetzt wird. Sie kann nicht nur bei elektiven und bei lang vorgeplanten Operationen effektiv und sicher durchgeführt werden, sondern auch mit wesentlich kürzerer Vorbereitungszeit, und ist, wie uns die Fallberichte der Zeugen Jehovahs lehren, auch eine zusätzliche Option bei Notfalleingriffen. Sie ist sicher und unbedenklich, wenn die Pharmakologie der ESP sowie der Hämoglobin-Indikationsbereich von 10–13 g/dL beachtet und eine medikamentöse Thromboseprophylaxe durchgeführt werden. Nicht empfohlen ist sie als generelles Programm für jeden Patienten, für die Anämie beim kritisch Kranken auf der Intensivstation und bei der Anämie des Frühgeborenen. Die Evidenzlage für die einzelnen in diesem Kapitel gegebenen Daten wird aus der 2015/2016 zu erwartenden AWMF Leitlinie ’präoperative Anämie’ klar ersichtlich sein.
Literatur
1.
Lin DM, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transfusion medicine reviews, 27: 221–234, 2013
2.
Beattie WS, Karkouti K, Wijeysundera DN, Tait G. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology, 110: 574–581, 2009CrossRefPubMed
3.
Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion, 42: 812–818, 2002CrossRefPubMed
4.
Hebert PC, Carson JL. Transfusion threshold of 7 g per deciliter–the new normal. The New England journal of medicine, 371: 1459–1461, 2014CrossRefPubMed
5.
Carson JL, Sieber F, Cook DR et al. Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet, 385: 1183–1189, 2014
6.
Carson JL, Hebert PC. Should we universally adopt a restrictive approach to blood transfusion? It's all about the number. The American journal of medicine, 127: 103–104, 2014CrossRefPubMed
7.
Shander A, Javidroozi M, Naqvi S, Aregbeyen O, Caylan M, Demir S, Juhl A. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion, 54: 2688-2695; quiz 2687, 2014
8.
Jo KI, Shin JW, Choi TY, Park YJ, Youm W, Kim MJ. Eight-year experience of bloodless surgery at a tertiary care hospital in Korea. Transfusion, 53: 948–954, 2013CrossRefPubMed
9.
Bretagnol A, Tamburini J, Guedj M, Denier C, Pene F. Profound anaemia and acute blindness in a Jehovah's Witness. Lancet, 382: 998, 2013CrossRefPubMed
10.
Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet, 378: 1396–1407, 2011CrossRefPubMed
11.
Jelkmann W. Physiology and pharmacology of erythropoietin. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 40: 302–309, 2013
12.
Lorentz A, Eckardt KU, Osswald PM, Kruse C. Perioperative plasma erythropoietin levels in hip arthroplasty. Annals of hematology, 68: 117–124, 1994CrossRefPubMed
13.
Nogueras S, Merino A, Ojeda R, Carracedo J, Rodriguez M, Martin-Malo A, Ramirez R, Aljama P. Coupling of endothelial injury and repair: an analysis using an in vivo experimental model. American journal of physiology Heart and circulatory physiology, 294: H708–713, 2008CrossRefPubMed
14.
Hirata Y, Nagata D, Suzuki E, Nishimatsu H, Suzuki J, Nagai R. Diagnosis and treatment of endothelial dysfunction in cardiovascular disease. International heart journal, 51: 1–6, 2010CrossRefPubMed
15.
Fliser D, Bahlmann FH. Erythropoietin and the endothelium - a promising link? Eur J Clin Invest, 38: 457–461, 2008CrossRefPubMed
16.
Frietsch T. Wirkungen systemischer und zerebraler Erythropoetin-Überexpression : Untersuchungen an transgenen Mäusen und an Ratten. Heidelberg, Univ., Habil.-Schr., 2003, 2002 pp 95 Bl
17.
Wang L, Di L, Noguchi CT. Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. International journal of biological sciences, 10: 921–939, 2014PubMedCentralCrossRefPubMed
18.
Sinclair AM, Coxon A, McCaffery I et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood, 115: 4264–4272, 2010CrossRefPubMed
19.
Elliott S, Busse L, Swift S, McCaffery I, Rossi J, Kassner P, Begley CG. Lack of expression and function of erythropoietin receptors in the kidney. Nephrology Dialysis Transplantation, 27: 2733–2745, 2012CrossRef
20.
Scott CL, Robb L, Papaevangeliou B, Mansfield R, Nicola NA, Begley CG. Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor. Blood, 96: 1588–1590, 2000PubMed
21.
Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, Begley CG, Elliott S. Absence of functional EpoR expression in human tumor cell lines. Blood, 115: 4254–4263, 2010CrossRefPubMed
22.
Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 362: 1255–1260, 2003CrossRefPubMed
23.
Goodnough LT, Shander A Current status of pharmacologic therapies in patient blood management. Anesth Analg, 116: 15–34, 2013CrossRefPubMed
24.
Gimenez LF, Scheel PJ. Clinical application of recombinant erythropoietin in renal dialysis patients. In: Erythropoietin: Basic and Clinical Aspects. edited by SPIVAK, P. V., Philadelphia PA, WB Saunders, 1994, pp 913–932
25.
Besarab A. Physiological and pharmacodynamic considerations for route of EPO administration. Seminars in nephrology, 20: 364–374, 2000
26.
Besarab A, Amin N, Ahsan, M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. Journal of the American Society of Nephrology : JASN, 11: 530–538, 2000PubMed
27.
Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. The Cochrane database of systematic reviews, 1: Cd 007857, 2012
28.
Besarab A, Reyes CM, Hornberger J. Meta-analysis of subkutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 40: 439–446, 2002CrossRef
29.
Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. ClinicoEconomics and outcomes research : CEOR, 6: 319–330, 2014
30.
Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. The Cochrane database of systematic reviews, 5: CD 003895, 2014
31.
Besarab A, Goodkin DA, Nissenson AR. The normal hematocrit study–follow-up. The New England journal of medicine, 358: 433–434, 2008CrossRefPubMed
32.
Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. The New England journal of medicine, 355: 2085–2098, 2006
33.
Macdougall IC. CREATE: new strategies for early anaemia management in renal insufficiency. Nephrology Dialysis Transplantation, 18 Suppl 2: ii13–16, 2003
34.
Mix TC, Brenner RM, Cooper ME et al. Rationale–Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American heart journal, 149: 408–413, 2005CrossRefPubMed
35.
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. The New England journal of medicine, 316: 73–78, 1987CrossRefPubMed
36.
Goodnough LT, Price TH, Rudnick S, Soegiarso RW. Preoperative red cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion, 32: 441–445, 1992CrossRefPubMed
37.
Wittig M, Osswald PM, Lorentz A, Jani L. Deposit of autologous blood at short intervals. Anaesthesist, 43: 9–15, 1994CrossRefPubMed
38.
Singbartl G, Malgorzata S, Quoss A. Preoperative autologous blood donation - part II. Adapting the predeposit concept to the physiological basics of erythropoiesis improves its efficacy. Minerva anestesiologica, 73: 153–160, 2007
39.
Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell volume expansion in autologous blood donors for elective orthopedic operation. Journal of the American College of Surgeons, 179: 171–176, 1994PubMed
40.
Agency EM. Epoetin Alfa Hexal. www, European Medicines Agency 2012 pp 3
41.
Wolff M, Fandrey J, Hirner A, Jelkmann W. Perioperative use of recombinant human erythropoietin in patients refusing blood transfusions. Pathophysiological considerations based on 5 cases. European journal of haematology, 58: 154–159, 1997CrossRefPubMed
42.
Tomeczkowski J, Fritze J. Preoperative anaemia in major elective orthopedic surgery: efficacy, safety and cost-effectiveness. Anasthesiologie & Intensivmedizin, 52: 217–227, 2011
43.
Kotze A, Carter LA, Scally AJ. Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. British journal of anaesthesia, 108: 943–952, 2012CrossRefPubMed
44.
Delasotta LA, Rangavajjula A, Frank ML, Blair J, Orozco F, Ong A. The Use of Preoperative Epoetin-alpha in Revision Hip Arthroplasty. The open orthopaedics journal, 6: 179–183, 2012PubMedCentralCrossRefPubMed
45.
Delasotta LA, Rangavajjula AV, Frank ML et al. The Use of Epoetin-alpha in Revision Knee Arthroplasty. Advances in orthopedics, 2012: 595027, 2012
46.
Tonia T, Mettler A, Robert N, Schwarzer G et al. Erythropoietin or darbepoetin for patients with cancer. The Cochrane database of systematic reviews, 12: Cd 003407, 2012
47.
Devon KM, McLeod RS. Pre and peri-operative erythropoietin for reducing allogeneic blood transfusions in colorectal cancer surgery. The Cochrane database of systematic reviews: Cd 007148, 2009
48.
Stowell CP, Jones SC, Enny C, Langholff W, Leitz G. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine, 34: 2479–2485, 2009CrossRefPubMed
49.
50.
Fergusson D. Management of perioperative anemia: Human Erythropoietin. In: GROUP, L. (Ed.) NATA 9th Annual Symposium Lisbon, Network for Advancement of Transfusion Alternatives, 2008
51.
Rizzo JD, Brouwers M, Hurley P et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood, 116: 4045–4059, 2010CrossRefPubMed
52.
Suttorp MM, Hoekstra T, Ocak G et al. Erythropoiesis-stimulating agents and thrombotic events in dialysis patients. Thrombosis research, 134: 1081–1086, 2014
53.
Glaspy J, Dunst J. Can erythropoietin therapy improve survival? Oncology, 67 Suppl 1: 5–11, 2004CrossRef
54.
Goodnough LT, Shander A. Update on erythropoiesis-stimulating agents. Best practice & research Clinical anaesthesiology, 27: 121–129, 2013
55.
Sienas L, Wong T, Collins R, Smith J. Contemporary Uses of Erythropoietin in Pregnancy: A Literature Review. Obstetrical & Gynecological Survey, 68: 594–602, 2013CrossRef
56.
Jansen Cilaq GmbH. Fachinformation ERYPO. 2009
57.
Manns BJ, Tonelli M. The New FDA Labeling for ESA—Implications for Patients and Providers. Clinical Journal of the American Society of Nephrology : CJASN, 7: 348–353, 2012
58.
Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. The Cochrane database of systematic reviews, 4: Cd 004863, 2014
59.
Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. The Cochrane database of systematic reviews, 4: Cd 004868, 2014
60.
Palmer SC, Saglimbene, V Craig, JC et al. Darbepoetin for the anaemia of chronic kidney disease. The Cochrane database of systematic reviews, 3: Cd 009297, 2014
61.
62.
Möllmann M. Erythropoietin–physiology and therapeutic potentialities. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 27: 461–468, 1992
63.
Hasegawa Y, Takamatsu J, Iwase T et al. Effects of recombinant human erythropoietin on thrombosis and fibrinolysis in autologous transfusion for hip surgery. Archives of orthopaedic and trauma surgery, 119: 384–387, 1999CrossRefPubMed
64.
Lorentz A, Eckardt KU, Osswald PM, Duchow JR. Erythropoietin in levels in patients depositing autologous blood in short intervals. Annals of hematology, 64: 281–285, 1992CrossRefPubMed
65.
Eckardt KU, Lorentz A, Kurtz A. Oxygen-dependent erythropoietin production: Basis for compensation of blood losses. In: [Contributions to Infusion Therapy; Homologous blood saving methods in surgical medicine]. edited by Schleinzer, W., Singbartl, G., 1993, pp 228–239
66.
Lorentz A, Jendrissek A, Eckardt KU, Schipplick M, Osswald PM, Kurtz A. Serial immunoreactive erythropoietin levels in autologous blood-donors. Transfusion, 31: 650–654, 1991CrossRefPubMed
67.
Lorentz A. Concerning: Gesemann M, et al.: Association of erythropoiesis during autologous blood donation with initial hemoglobin concentration and length of donation period. Infusionsther Transfusionsmed 1999;26 : 353-359. Infusion Therapy and Transfusion Medicine-Infusionstherapie Und Transfusionsmedizin, 27: 157–157, 2000
68.
Sowade O, Ziemer S, Sowade B et al. The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. The Journal of laboratory and clinical medicine, 129: 376–383, 1997CrossRefPubMed
69.
Heiss MM, Tarabichi A, Delanoff C et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery, 119: 523–527, 1996CrossRefPubMed
70.
Lorentz A, Jendrissek A, Eckardt KU, Schipplick M, Osswald PM, Kurtz A: Serial immunoreactive erythropoietin levels in autologous blood donors. Transfusion, 31: 650–654, 1991CrossRefPubMed
71.
Mollmann M, Lubbesmeyer HJ, von Bormann B, Friedrich M, Schleinzer W, Brodner G: Erythropoietin therapy during frequent autologous blood donations. Dose-finding study. Anaesthesist, 44: 624–630, 1995CrossRefPubMed
72.
Rosencher N, Ozier Y. Érythropoïétine en péri-opératoire. Transfusion Clinique et Biologique, 10: 159–164, 2003CrossRefPubMed
73.
Weisbach V, Skoda P, Rippel R, Lauer G, Glaser A, Zingsem J, Zimmermann R, Eckstein R. Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion, 39: 465–472, 1999CrossRefPubMed
74.
Rosencher N, Ozier Y. Peri-operative use of EPO. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 10: 159–164, 2003
75.
Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox sanguinis, 75: 128–133, 1998CrossRefPubMed
76.
Goodnough LT. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy. Nephrology Dialysis Transplantation, 17 Suppl 5: 14–18, 2002
77.
Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 177: 725–734, 2007
78.
Napolitano LM, Fabian TC, Kelly KM et al. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. The Journal of trauma, 65: 85–297; discussion 297-289, 2008.
79.
Goodnough LT, Maniatis A, Earnshaw P et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. British journal of anaesthesia, 106: 13–22, 2011PubMedCentralCrossRefPubMed
80.
IAKH: Rote-Hand-Brief zu allen Eisen-Präparaten zur intravenösen Applikation: Risiko schwerer Überempfindlichkeitsreaktionen. In: Frietsch, T. (Ed.) wwwiakhde/nachrichten. http://​www.​Iakh.​de, 2013
81.
Posluszny JA, Napolitano LM. How do we treat life-threatening anemia in a Jehovah's Witness patient? Transfusion, 54: 3026–3034, 2014CrossRefPubMed
82.
Heh-Foster AM, Naber M, Pai MP, Lesar TS. Epoetin in the 'untransfusable' anaemic patient: a retrospective case series and systematic analysis of literature case reports. Transfusion medicine (Oxford, England), 24: 204–208, 2014CrossRef
83.
de Araujo Azi LM Lopes FM Garcia LV. Postoperative management of severe acute anemia in a Jehovah's Witness. Transfusion, 54: 1153–1157, 2014CrossRef
84.
Beliaev AM, Marshall RJ, Smith W, Windsor JA. Mortality risk stratification in severely anaemic Jehovah's Witness patients. Internal medicine journal, 42: e1–3, 2012
85.
Ball AM, Winstead PS. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. Pharmacotherapy, 28: 1383–1390, 2008CrossRefPubMed
86.
Corwin HL, Gettinger A, Pearl RG et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. Jama, 288: 2827–2835, 2002CrossRefPubMed
87.
Duby JJ, Erstad BL, Abarca J, Camamo JM, Huckleberry Y, Bramblett SN. Impact of delayed initiation of erythropoietin in critically ill patients. BMC blood disorders, 7: 1, 2007
88.
Kanakaris NK, Petsatodis, G Chalidis, B et al. The role of erythropoietin in the acute phase of trauma management: evidence today. Injury, 40: 21–27, 2009
89.
Jelkmann I, Jelkmann W. Impact of erythropoietin on intensive care unit patients. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 40: 310–318, 2013
90.
McIntyre L, Tinmouth AT, Fergusson DA. Blood component transfusion in critically ill patients. Current opinion in critical care, 19: 326–333, 2013
91.
Diamond PT. Severe anaemia: implications for functional recovery during rehabilitation. Disability and rehabilitation, 22: 574–576, 2000
92.
Halm EA, Wang JJ, Boockvar K et al. The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. Journal of orthopaedic trauma, 18: 369–374, 2004PubMedCentralCrossRefPubMed
93.
Yoon J, Kim S, Lee SC, Lim H. Postoperative high-dose intravenous iron sucrose with low dose erythropoietin therapy after total hip replacement. The Korean journal of internal medicine, 25: 454–457, 2010PubMedCentralCrossRefPubMed
94.
Ranucci M, La Rovere MT, Castelvecchio S et al. Postoperative anemia and exercise tolerance after cardiac operations in patients without transfusion: what hemoglobin level is acceptable? The Annals of thoracic surgery, 92: 25–31, 2011CrossRefPubMed
95.
Johnson RG, Thurer RL, Kruskall MS et al. Comparison of two transfusion strategies after elective operations for myocardial revascularization. The Journal of thoracic and cardiovascular surgery, 104: 307–314, 1992PubMed
96.
Foss NB, Kristensen MT, Jensen PS, Palm H, Krasheninnikoff M, Kehlet H. The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion, 49: 227–234, 2009CrossRefPubMed
97.
Cladellas M, Farre N, Comin-Colet J et al. Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. The American journal of cardiology, 110: 1021–1026, 2012CrossRefPubMed
98.
Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology, 115: 929–937, 2011CrossRefPubMed
99.
Hogan M, Klein AA, Richards T. The impact of anaemia and intravenous iron replacement therapy on outcomes in cardiac surgery. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 47: 218–226, 2015CrossRef
100.
Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart J. 36: 657–668, 2014
101.
Anker SD, Colet JC, Filippatos G et al. Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European journal of heart failure, 11: 1084–1091, 2009PubMedCentralCrossRefPubMed
102.
103.
Ehrenreich H, Weissenborn K, Prange H et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke, 40: e647–656, 2009CrossRefPubMed
104.
Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best practice & research Clinical anaesthesiology, 24: 573–594, 2010
105.
Fertrin KY, Lanaro C, Franco-Penteado CF et al. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15. American journal of hematology, 89: 385–390, 2014CrossRefPubMed
106.
Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature genetics, 46: 678–684, 2014PubMedCentralCrossRefPubMed
107.
D'Anna MC, Roque ME. Physiological focus on the erythropoietin-hepcidin-ferroportin axis. Canadian journal of physiology and pharmacology, 91: 338–345, 2013
108.
Creange A, Lefaucheur JP, Balleyguier MO, Galacteros F. Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis: a pilot, open-label study with neurophysiological measurements. Neurophysiologie clinique = Clinical neurophysiology, 43: 303–312, 2013
109.
Sonnenberg FA, Gregory P, Yomtovian R, Russell LB, Tierney W, Kosmin M, Carson JL. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion, 39: 808–817, 1999CrossRefPubMed
110.
Tomeczkowski J, Stern S, Müller A, von Heymann C. Potential Cost Saving of Epoetin alfa in Elective Hip or Knee Surgery due to Reduction in Blood Transfusions and Their Side Effects: A Discrete-Event Simulation Model. PLoS ONE, 8, 2013
111.
Coyle D, Lee KM, Fergusson DA, Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfusion medicine (Oxford, England), 9: 21–30, 1999CrossRef
112.
Coyle D, Lee KM, Fergusson DA, Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. PharmacoEconomics, 18: 161–171, 2000CrossRefPubMed
113.
Marchetti M, Barosi G. Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery. Transfusion, 40: 673–681, 2000CrossRefPubMed
114.
Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health technology assessment (Winchester, England), 10: iii-iv, ix-x, 1-210, 2006
115.
Singbartl G, Schleinzer W. Cost analysis of autologous transfusion methods–a study of 5,017 patients. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 34: 350–358, 1999
116.
So-Osman C, Nelissen RG, Koopman-van Gemert AW et al. Patient blood management in elective total hip- and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology, 120: 839–851, 2014CrossRefPubMed
Metadaten
Titel
Erythropoese stimulierende Pharmaka (ESP)
verfasst von
Prof. Dr. med. Thomas Frietsch
Copyright-Jahr
2016
Verlag
Springer Berlin Heidelberg
Buch
Transfusionsassoziierte Pharmakotherapie

Print ISBN: 978-3-662-47257-6

Electronic ISBN: 978-3-662-47258-3

Copyright-Jahr: 2016

DOI
https://doi.org/10.1007/978-3-662-47258-3_2

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 | Pankreaskarzinom | Nachrichten

S3-Leitlinie zu Pankreaskrebs aktualisiert
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren